Our Pricing

Mounjaro in Pershore: Expert Weight Loss Support

Published: 2 October 2026

Residents seeking Mounjaro Pershore now have access to transparent, clinically supervised weight loss treatment through Cured Pharmacy's UK-registered online service. Our platform connects Pershore patients with GMC-registered prescribers who assess suitability for tirzepatide injections, ensuring safe access to this MHRA-licensed medication without the need to visit a physical pharmacy. With pricing from £124.99 and discreet home delivery across Worcestershire, we've supported thousands of patients in achieving meaningful weight reduction under expert clinical guidance.

How Mounjaro Pershore Services Work Through Cured Pharmacy

Accessing Mounjaro Pershore treatment begins with a comprehensive online clinical assessment completed in under three minutes. Our UK-registered prescribers review your medical history, current medications, weight loss goals, and contraindications to determine whether tirzepatide is appropriate for your individual circumstances. This digital consultation meets the same rigorous standards as face-to-face GP appointments, ensuring patient safety remains paramount throughout the prescribing process [1].

Once approved, your Mounjaro prescription is dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Medications are sourced exclusively from UK-licensed wholesalers and delivered in 100% discreet packaging to addresses across Pershore and surrounding Worcestershire areas. Our transparent pricing model displays the £124.99 cost upfront, with an additional £20 off your first order using code Weightlossnew, eliminating unexpected fees common with traditional pharmacy services.

Clinical Evidence Supporting Mounjaro Pershore Prescriptions

The decision to prescribe Mounjaro Pershore patients is grounded in robust clinical trial data demonstrating tirzepatide's efficacy as a weight management intervention. The SURMOUNT-1 trial showed participants achieved an average weight reduction of 20.9% over 72 weeks when using the 15mg maintenance dose, significantly outperforming placebo groups [2]. These results have positioned tirzepatide as one of the most effective pharmacological options for adults with obesity or weight-related comorbidities.

Tirzepatide functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, modulating appetite regulation pathways in the hypothalamus whilst slowing gastric emptying [3]. This dual mechanism distinguishes Mounjaro from single-agonist treatments, contributing to superior weight loss outcomes observed across clinical populations. Our prescribers evaluate whether these benefits align with each Pershore patient's metabolic profile and weight management objectives.

MHRA Licensing and UK Regulatory Status

Mounjaro received MHRA approval for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, following comprehensive review of safety and efficacy data [4]. This regulatory clearance ensures that Mounjaro Pershore prescriptions meet stringent UK pharmaceutical standards. Our clinical team adheres strictly to MHRA prescribing guidelines, ensuring treatment is only initiated when clinically appropriate and after thorough patient assessment.

Mounjaro Pershore Dosing Protocols and Treatment Timelines

Treatment initiation for Mounjaro Pershore patients follows a structured dose-escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic response. Patients begin with a 2.5mg subcutaneous injection once weekly for four weeks, progressing to 5mg for an additional four weeks. Subsequent increases to 7.5mg, 10mg, 12.5mg, and ultimately 15mg occur at four-week intervals, subject to individual tolerance and clinical response [1].

Our prescribers monitor progress through follow-up consultations, assessing weight loss trajectory, side effect profiles, and adherence to lifestyle modifications including dietary adjustments and physical activity. Mounjaro Pershore treatment is most effective when integrated into a comprehensive weight management programme rather than used as a standalone intervention. Patients typically observe initial weight reduction within the first month, with peak efficacy achieved after 16-20 weeks on therapeutic doses [2].

Mounjaro Pershore Pricing Transparency and Cost Breakdown

Cured Pharmacy offers Mounjaro Pershore residents clear, upfront pricing starting from £124.99 per four-week supply, with no hidden consultation fees or membership charges. This transparent cost structure contrasts with traditional pharmacy models where final pricing is often obscured until after clinical assessment. New patients receive £20 off their initial order using code Weightlossnew, reducing the first month's cost to £124.99.

The price reflects genuine UK-licensed medication dispensed through regulated channels, ensuring product authenticity and cold-chain integrity throughout storage and transit. We do not stock grey-market or compounded tirzepatide formulations, which may compromise patient safety despite lower pricing. Our commitment to competitive UK pricing ensures Pershore patients access clinically supervised weight loss treatment without financial barriers that prevent adherence to long-term therapy.

Insurance and Private Prescription Considerations

Mounjaro Pershore prescriptions issued through Cured Pharmacy are private prescriptions not reimbursed by the NHS. Patients should verify whether private medical insurance policies cover GLP-1 receptor agonists for weight management, as coverage varies significantly between providers. Our clinical team provides itemised receipts suitable for insurance claim submissions where applicable.

Safety Profile and Contraindications for Mounjaro Pershore Patients

Common side effects reported by Mounjaro Pershore users include nausea, diarrhoea, decreased appetite, vomiting, and constipation, typically most pronounced during dose-escalation phases [3]. These gastrointestinal symptoms generally diminish as the body adapts to tirzepatide, though persistent or severe reactions warrant prescriber consultation. Our clinical team provides tailored guidance on managing side effects through dietary modifications, hydration strategies, and dose adjustment when clinically indicated.

Absolute contraindications for Mounjaro Pershore treatment include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and hypersensitivity to tirzepatide or excipients [4]. Patients with severe gastroparesis, diabetic retinopathy complications, or acute pancreatitis history require careful risk-benefit evaluation. Our online assessment captures these critical safety parameters, ensuring prescribers identify unsuitable candidates before treatment initiation.

Mounjaro Pershore Delivery and Ongoing Clinical Support

Once your Mounjaro Pershore prescription is approved, medications are dispatched via temperature-controlled courier services maintaining the 2-8°C cold chain required for tirzepatide stability. Deliveries arrive in discreet, unmarked packaging with no external indication of contents, protecting patient privacy throughout the fulfilment process. Standard delivery to Pershore addresses completes within 1-2 working days, with tracking information provided at dispatch.

Ongoing clinical support includes access to our UK-registered pharmacist team via phone (+44 116 4646009) for injection technique guidance, side effect management, and general medication queries. Follow-up prescriptions require repeat clinical assessment to monitor treatment efficacy, assess continued suitability, and adjust dosing protocols based on individual response. This continuous care model ensures Mounjaro Pershore patients receive the same standard of clinical oversight as traditional in-person pharmacy services whilst benefiting from digital convenience and competitive pricing.

Storage and Handling Instructions for Pershore Patients

Mounjaro KwikPens must be refrigerated at 2-8°C until first use, after which they may be stored at room temperature (below 30°C) for up to 21 days [1]. Pershore patients should avoid freezing pens or exposing them to direct sunlight, as temperature extremes compromise medication potency. Our pharmacy team provides comprehensive storage guidance with each dispensation to ensure optimal therapeutic efficacy throughout the treatment course.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Eli Lilly and Company Limited. [accessed 2 October 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 2 October 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 2 October 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg solution for injection in pre-filled pen. MHRA. [accessed 2 October 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 2 October 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 2 October 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 2 October 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.